QHRD 106
Alternative Names: PEG-tissue kallikrein-1; Pegylated(PEG)-tissue kallikrein-1; QHRD-106Latest Information Update: 09 May 2024
At a glance
- Originator Changzhou Qianhong Bio-pharma
- Class Polyethylene glycols; Vascular disorder therapies
- Mechanism of Action Bradykinin B2 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Stroke
Most Recent Events
- 25 Dec 2023 Changzhou Qianhong Bio-pharma completes a phase I trial in Stroke (In Volunteers) in China (NCT06380699)
- 27 Jul 2023 Pharmacodynamics data from a preclinical trial in Stroke released by Changzhou Qianhong Biopharma
- 16 Mar 2023 Preclinical trials in Stroke in China (IM) prior to March 2023.